Linkedin X-twitter
Search

+44 (0)20 7722 1221

[email protected]

VIEW OPPORTUNITIES

SHARE

AstraZeneca reiterates guidance

The drug maker reported a 13% increase in core operating profit to $9.4bn for H1, while total revenues rose 11% to $28bn, driven by double-digit growth in oncology and biopharmaceuticals. These results led to the company reiterating its guidance for 2025.
Read the full article.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.